Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 1997

View Archived Issues

Sepracor's levalbuterol NDA accepted by FDA

ICOS and Abbott expand collaboration

Vertex and Alpha Therapeutic end hemoglobin collaboration

Anika completes phase III trial on Orthovisc

Activated Cell Therapy now named Dendreon Corporation

SmithKline Beecham and Incyte form diaDexus

Improved IOP-lowering prostaglandin analogues from Alcon

DuPont Merck discloses new anticoagulants

Large, long-term trial evaluates association between heart rate and mortality

Role of vitamin C in cardiovascular diseases investigated

Lipoprotein(a): new insights into the process of atherosclerosis

Subtype-selective NMDA receptor ligands reported

CV Therapeutics: Q2 1997 highlights

Celltech prepares PDE IV inhibitors

Vitronectin receptor antagonists described by Merck KGaA

Nippon Roche: products under development

DANAMI trial results presented

Texas Biotechnology: Q2 1997 highlights

Merck's asthma treatment receives first approvals

Genzyme General's Seprafilm receives approval in Japan

Neurobiological Technologies files IND for antiedema agent

AccuSite approved in Ireland and The Netherlands

Spotlight on adenosine A1 receptor agonists

DepoTech seeks Canadian approval for DepoCyt

Xoma: Q2 1997 highlights

NeuroSearch compound enters phase I for treatment of dementia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...